Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Leases (2019 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Current Leases for 7 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 45.6% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 45.6% increase, with the full-year FY2025 number at $4.2 million, up 45.6% from a year prior.
  • Current Leases was $4.2 million for Q4 2025 at Cartesian Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $4.2 million in Q4 2025 to a low of $942000.0 in Q1 2021.
  • A 5-year average of $2.1 million and a median of $1.8 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 40.72% in 2021, then skyrocketed 66.17% in 2025.
  • Cartesian Therapeutics' Current Leases stood at $1.0 million in 2021, then skyrocketed by 53.29% to $1.6 million in 2022, then surged by 34.7% to $2.2 million in 2023, then skyrocketed by 31.63% to $2.9 million in 2024, then surged by 45.6% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Current Leases are $4.2 million (Q4 2025), $3.9 million (Q3 2025), and $3.8 million (Q2 2025).